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Abstract
Background: Limited data is available to guide the choice of the conditioning regimen for patients with acute
myeloid leukemia (AML) undergoing transplant with persistent disease.
Methods: We retrospectively compared outcome of fludarabine-treosulfan (FT), thiotepa-busulfan-fludarabine (TBF),
and sequential fludarabine, intermediate dose Ara-C, amsacrine, total body irradiation/busulfan, cyclophosphamide
(FLAMSA) conditioning in patients with refractory or relapsed AML.
Results: Complete remission rates at day 100 were 92%, 80%, and 88% for FT, TBF, and FLAMSA, respectively
(p = 0.13). Non-relapse mortality, incidence of relapse, acute (a) and chronic (c) graft-versus-host disease
(GVHD) rates did not differ between the three groups. Overall survival at 2 years was 37% for FT, 24% for TBF,
and 34% for FLAMSA (p = 0.10). Independent prognostic factors for survival were Karnofsky performance score
and patient CMV serology (p = 0.01; p = 0.02), while survival was not affected by age at transplant. The use of
anti-thymocyte globulin (ATG) was associated with reduced risk of grade III–IV aGVHD (p = 0.02) and cGVHD
(p = 0.006), with no influence on relapse.
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Conclusions: In conclusion, FT, TBF, and FLAMSA regimens provided similar outcome in patients undergoing
transplant with active AML. Survival was determined by patient characteristics as Karnofsky performance score
and CMV serology, however was not affected by age at transplant. ATG appears able to reduce the incidence
of acute and chronic GVHD without influencing relapse risk.
Keywords: Acute myeloid leukemia (AML), Active disease, Allogeneic transplantation, Sibling donor (MSD),
Unrelated donor (UD), Conditioning regimen, Fludarabine-treosulfan (FT), Thiotepa-busulfan-fludarabine (TBF),
Fludarabine, intermediate dose Ara-C, amsacrine, total body irradiation/busulfan, cyclophosphamide (FLAMSA)
Background
Allogeneic hematopoietic stem cell transplant is the only
potentially curative option for patients with acute mye-
loid leukemia (AML) in primary induction failure or re-
fractory relapse. This population represents a big
challenge for transplant physicians; nevertheless, accord-
ing to recent evidence [1, 2], long-term survival can be
achieved in about one third of patients undergoing
transplant with active leukemia, and recent recommen-
dations support prompt transplant in this setting, avoid-
ing further chemotherapy [3]. The choice of the
conditioning regimen is of vast importance in these fra-
gile patients, as the need for powerful cytoreduction
should not negate an acceptable toxicity profile of the
protocol [4]. Historically, regimens employed in this set-
ting included mainly standard myeloablative protocols
based on alkylators or total-body irradiation (TBI) [5–7].
More recently, alternative strategies have been devel-
oped. The sequential fludarabine, intermediate dose
Ara-C, amsacrine, total body irradiation/busulfan, cyclo-
phosphamide (FLAMSA) regimen, designed by Kolb and
colleagues in the early 2000s [8, 9], has shown promising
outcome and currently represents one of the most widely
employed protocols in this setting. On the other hand, the
relentless effort of transplant physicians to temper condi-
tioning toxicity while retaining a significant myeloablative
power recently prompted the design of novel regimens,
taking advantage in time of rather old drugs like thiotepa
or treosulfan or combining two alkylators at reduced
doses. The combination of thiotepa, busulfan, and fludara-
bine (TBF) was initially proposed as a preparative regimen
for cord blood transplant [10]; subsequently, it has dem-
onstrated excellent anti-leukemic activity in haploidentical
[11, 12], matched sibling donor (MSD) and unrelated
donor (UD) transplant [13, 14]. An additional option is
represented by the association of fludarabine and treosul-
fan (FT), which has been intensely investigated in the last
decade [15–18]. Preliminary results of a prospective ran-
domized trial demonstrated promising outcome following
FT conditioning in patients with AML and MDS [19]. Fur-
thermore, in a recent retrospective study comparing treo-
sulfan with busulfan-based regimens in patients with
active leukemia at the time of transplant, FT protocol re-
sulted in improved outcome [20]. Given the lack of avail-
able reports analyzing and comparing the alternative
conditioning protocols in patients with refractory or re-
lapsed AML, we designed the current study to compare
outcome of FT, TBF, and FLAMSA regimens in this par-
ticularly challenging setting.
Methods
Study design and data collection
This is a registry-based retrospective study. Data were pro-
vided and the study design was approved by the Acute
Leukemia Working Party (ALWP) of the European Society
for Blood and Marrow Transplantation (EBMT), in accord-
ance with the EBMT guidelines for retrospective studies.
EBMT is a voluntary working group of more than 600
transplant centers which are required to report all consecu-
tive stem cell transplantations and follow-up once a year.
Audits are routinely performed to determine the accuracy
of the data. Since 1990, patients have been able to provide
informed consent that authorizes the use of their transplant
information for research purposes. The ALWP of the
EBMTgranted ethical approval for this study.
We included in the analysis AML patients older than
18 years, who had received FT, TBF, or FLAMSA as condi-
tioning regimen for transplant from matched sibling
donor (MSD) or unrelated donor (UD) as first transplant
in active disease status (defined as > 5% bone marrow
blasts or detectable blasts in peripheral blood at the time
of transplant). Patients with primary refractory AML, first
or second relapse were included in the analysis. Stem cell
transplants were performed between January 2005 and
December 2016, and all data were reported to the ALWP
of the EBMT. All unrelated donors were HLA-matched
(10/10) or mismatched at one HLA locus (9/10). Patients
who received conditioning regimens including oral busul-
fan or T-depleted grafts were excluded.
End-point definitions and statistical analysis
Non-relapse mortality (NRM) was defined as death from
any cause in the absence of prior disease recurrence.
Disease relapse was defined according to standard
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hematologic criteria. Leukemia-free survival (LFS) was
defined as survival without relapse. Overall survival (OS)
was calculated from the day of transplant until death
from any cause or last follow-up. GVHD-free
relapse-free survival (GRFS) was defined by the first of
the following events: acute GVHD grades III to IV, ex-
tensive chronic GVHD, relapse, or death [21]. Patients
with no event were censored at last contact. The cause
of death was categorized according to standard criteria.
The cause of death of patients who experienced relapse
at any time before death was considered relapse related.
Acute and chronic GVHD were graded according to
standard criteria. All outcomes were measured from the
time of stem cell infusion. Follow-up was estimated
using the reverse Kaplan-Meier method. LFS, OS, and
GRFS were estimated using the Kaplan-Meier method
[22], whereas NRM, relapse, and GVHD were estimated
using cumulative incidence analysis considering compet-
ing risks [23]. Univariate comparisons were performed
using the log-rank test for LFS, OS, and GRFS and
Gray’s test for GVHD, relapse incidence, and NRM. For
all univariate analyses, continuous variables were catego-
rized and the median used as a cut-off point. Multivari-
ate analyses were performed using the Cox proportional
hazards model. All factors differing significantly in distri-
bution between the three groups or associated with one
outcome were included in the Cox model. The FLAMSA
group was used as the reference group in all compari-
sons. Results are expressed as hazard ratio (HR) with
95% confidence interval (CI). All p values were
two-sided, and p < 0.05 were considered statistically sig-
nificant. Statistical analyses were performed with SPSS
22.0 (IBM Corp., Armonk, NY) and R3.2.3 software
packages(R Development Core Team, Vienna, Austria).
Results
Patient, disease, and transplant characteristics
Eight hundred and fifty-six patients fulfilled the inclusion
criteria for the present analysis. Among them, 113 patients
received FT, 112 TBF, and 631 received the FLAMSA regi-
men. Three hundred and sixty-two patients (42%) were
transplanted from a MSD, 347 (41%) from a 10/10 UD,
and 147 (17%) from a 9/10 UD. The FLAMSA protocol
was busulfan- or TBI-based in 32% and 68% of the pa-
tients, respectively. Busulfan total dose was 6.4 mg/kg in
210 patients (157 FLAMSA, 53 TBF) and 9.6mg/kg in 61
patients (8 FLAMSA, 53 TBF), while it was 12.8mg/kg in
43 patients (37 FLAMSA, 6 TBF). In the group receiving
TBI as part of the FLAMSA regimen, the dose was 4 Gy
for all patients. Treosulfan dose was 30mg/m2, 36mg/m2,
or 42mg/m2 in 9, 21, and 83 patients, respectively.
Anti-thymocyte globulin (ATG) administration was more
frequent in FLAMSA as compared to TBF and FT cohorts
(88%, 58%, and 39%, respectively, p < 10−3). The median
year of transplant was 2011, 2015, and 2010 for FT, TBF,
and FLAMSA, respectively (p < 10−3). The FT group in-
cluded significantly older patients compared to the TBF
and FLAMSA cohorts (median age 58, 52, and 52 years,
respectively, p < 10−3). Cytogenetic data were available in
56% of the patients; among them, 6% of patients were with
favorable, 63% with intermediate, and 31% with adverse
cytogenetics, with no significant difference between the
three groups. Cytomegalovirus (CMV) serology of donor
and patient differed between the three cohorts (p < 10−3).
Disease status (primary refractory or relapsed AML), Kar-
nofsky performance score (KPS), type of donor, and
donor/patient gender match did not differ between the
groups. Donor lymphocyte infusions were administered to
101 (16%) patients in the FLAMSA group, 10 (9%) TBF
recipients, and 14 (13%) patients within the FT cohort.
Fifty-seven patients in the FLAMSA, 8 patients in the
TBF, and 6 patients in the FT group received a second
allogeneic transplant. Patient, disease, and transplant char-
acteristics are summarized in Table 1. Detailed informa-
tion on drug doses and post transplant cell therapy is
provided in the supplementary material (Additional file 1).
Engraftment, disease response, and graft-vs-host disease
Engraftment rate was 98%, 91%, and 95% with median
time to neutrophil engraftment of 16, 15, and 14 days in
the FT, TBF, and FLAMSA cohorts, respectively (p = 0.1;
p = 0.02). Median time to platelet engraftment was 15 days
in the TBF group and 14 days in FT and FLAMSA groups.
Graft failure was observed in four patients in the
FLAMSA group and in one patient in the TBF and FT
groups each. Secondary graft rejection was observed in six
patients in the FLAMSA group while in none of the
others. Cumulative incidence of complete remission for
patients that reached day 100 was 92%, 80%, and 88% for
the FT, TBF, and FLAMSA groups, respectively (p = 0.13).
Global incidence of grade II–IV and III–IV acute GVHD
(aGVHD) was 28% and 11%, respectively. The incidence
of grade II–IV aGVHD was similar between the three
groups, being 24%, 29%, and 28% in FT, TBF, and
FLAMSA, respectively (p = 0.7). Similarly, the incidence
of grade III–IV aGVHD did not differ between the three
cohorts, 10% for FT, 12% for TBF, and 11% for FLAMSA,
respectively (p = 0.9). Frequencies of chronic GVHD
(cGVHD) and severe cGVHD in the global population
were 27% and 12%, respectively. By univariate analysis, the
cumulative incidence of cGVHD and severe cGVHD was
similar in the three groups, being 33%, 26%, and 26% (p =
0.4) and 13%, 19%, and 11% (p = 0.5) for FT, TBF, and
FLAMSA, respectively (Additional file 1). In multivariate
analysis, the only factors associated with increased risk of
developing aGVHD were transplant from mismatched un-
related donor and female/male donor/patient gender
match. The use of ATG was independently associated with
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Table 1 Patient, disease, and transplant characteristics
FT TBF FLAMSA p
Number (total, 856) 113 112 631
Follow-up for survivors (months), median (95% CI) 53 (10–34) 16 (3–10) 53 (95% CI 4–35) < 0.001
Age of patient at HSCT (years), median (range) (IQR) 58 (21–76) (47–64) 52.1 (24.4–70.1) (38.1–61) 51.5 (18.1–76) (41.9–59.9) 0.001
Age of patient at HSCT (categorical), n (%) 0.028
< 50 years 35 (31%) 46 (41%) 280 (44%)
≥ 50 years 78 (69%) 66 (59%) 351 (56%)
Gender of patient, n (%) 0.09
Male 66 (59%) 71 (63%) 336 (53%)
Female 47 (41%) 41 (37%) 295 (47%)
Karnofsky performance status at SCT, n (%) 0.7
KPS < 80 14 (13%) 12 (11%) 61 (10%)
KPS≥ 80 95 (87%) 95 (89%) 523 (90%)
Missing 4 5 47
Cytogenetics, n (%) 0.6
Favorable 7 (6%) 2 (2%) 19 (3%)
Intermediate 37 (33%) 38 (34%) 228 (36%)
Adverse 20 (18%) 19 (17%) 112 (18%)
Missing 49 (43%) 53 (47%) 272 (43%)
Disease status, n (%) 0.2
Primary induction failure 73 (64%) 59 (53%) 344 (55%)
First relapse 30 (27%) 44 (39%) 241 (38%)
Second relapse 10 (9%) 9 (8%) 46 (7%)
Year of transplant, median (range) 2011 (2005–2016) 2015 (2007–2016) 2010 (2005–2016) < 0.001
Donor, n (%) 0.06
MSD 56 (49%) 54 (48%) 252 (40%)
UD 10/10 44 (39%) 35 (31%) 268 (42%)
UD 9/10 13 (12%) 23 (21%) 111 (18%)
Donor/recipient sex mismatch, n (%) 0.8
F to M 19 (18%) 21 (19%) 124 (20%)
No F to M 87 (82%) 91 (81%) 490 (80%)
Stem cell source, n (%) < 0.001
BM 4 (4%) 19 (17%) 15 (2%)
PBSCs 109 (96%) 93 (83%) 616 (98%)
CMV donor/recipient, n (%) < 0.001
Donor−/Recipient− 22 (21%) 13 (12%) 167 (27%)
Donor+/Recipient− 9 (8%) 8 (7%) 76 (12%)
Donor−/Recipient+ 21 (19%) 25 (23%) 140 (23%)
Donor+/Recipient+ 57 (52%) 61 (58%) 229 (37%)
ATG used, n (%) < 0.001
No 69 (61%) 46 (42%) 73 (12%)
Yes 44 (39%) 64 (58%) 554 (88%)
Some percentages do not add up to 100% because of rounding
ATG anti-thymocyte globulin, BM bone marrow, CMV cytomegalovirus, FLAMSA fludarabine, intermediate dose Ara-C, amsacrine, total body irradiation,
cyclophosphamide sequential regimen, KPS Karnofsky performance status, FT fludarabine-treosulfan, GVHD graft-versus-host disease, LFS leukemia-free survival,
MAC myeloablative, MSD matched sibling donor, NRM non-relapse mortality, OS overall survival, PBSCs peripheral blood stem cells, RI relapse incidence, TBF
thiotepa-busulfan-fludarabine, TBI total-body irradiation, UD unrelated donor
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reduced risk of grade III–IV aGVHD and cGVHD
(Table 2).
NRM, relapse, and survival
Global NRM rate was 7% at 100 days and 22% at 2 years.
Six (5%) patients following FT, 14 (13%) following TBF
and 40 (6%) following FLAMSA regimen died within
100 days. By univariate analysis, non-relapse mortality at
2 years was similar between the three groups: 26%, 24%,
and 20% in FT, TBF, and FLAMSA, respectively (p =
0.24) (Fig. 1). In multivariate analysis, factors associated
with increased NRM risk were older age and transplant
from mismatched UD (Table 2). Leading causes of NRM
were GVHD and infectious complications; the complete
list of causes of death and their relative incidence are de-
tailed in Table 3.
Cumulative incidence of relapse in the entire population
was 52% at 2 years. By univariate analysis, 2-year relapse
incidence was not statistically different between the three
groups; 46%, 54%, and 53% for FT, TBF, and FLAMSA, re-
spectively (p = 0.33). Multivariate analysis confirmed those
results. Factors independently associated with higher risk
Table 2 Multivariate analysis of transplantation outcome
Outcome HR 95% CI p
RI FLAMSA (ref) 1
TBF 0.9 0.6–1.4 0.6
FT 0.8 0.5–1.2 0.2
Age (per 10 years) 0.9 0.8–0.9 0.005
Relapse vs prim. ref 1.3 1.1–1.6 0.01
Patient CMV pos. 1.3 1.03–1.7 0.03
NRM FLAMSA (ref) 1
TBF 1.5 0.8–2.7 0.17
FT 1.2 0.7–2.1 0.5
Age (per 10 years) 1.3 1.1–1.5 0.002
MSD (reference) 1
UD 10/10 1.5 0.9–2.3 0.08
UD 9/10 1.8 1.1–2.9 0.03
LFS FLAMSA (ref) 1
TBF 1.1 0.7–1.5 0.7
FT 0.9 0.6–1.3 0.6
Patient CMV pos. 1.4 1.1–1.7 0.005
OS FLAMSA (ref) 1
TBF 1.2 0.8–1.7 0.3
FT 0.8 0.6–1.2 0.4
KPS≥ 80% 0.7 0.5–0.9 0.01
Patient CMV pos. 1.3 1.1–1.6 0.02
GRFS FLAMSA (ref) 1
TBF 0.9 0.7–1.4 0.9
FT 0.8 0.6–1.07 0.13
KPS≥ 80% 0.7 0.5–0.9 0.01
Patient CMV pos. 1.2 1.004–1.5 0.05
ATG used 0.8 0.6–1.01 0.06
aGVHD III–IV FLAMSA (ref) 1
TBF 0.9 0.4–2.1 0.8
FT 0.7 0.3–1.6 0.4
KPS≥ 80% 0.5 0.3–1.02 0.06
MSD (reference) 1
UD 10/10 1.6 0.8–2.9 0.16
UD 9/10 3.6 1.9–6.9 < 0.001
Female D to male R 1.7 1.01–2.9 0.045
ATG used 0.4 0.2–0.9 0.018
cGVHD FLAMSA (ref) 1
TBF 1.7 0.7–4.1 0.2
FT 0.7 0.3–1.6 0.4
Age (per 10 years) 0.8 0.7–0.9 0.03
ATG used 0.4 0.2–0.8 0.006
Severe cGVHD FLAMSA (ref) 1
TBF 1.4 0.6–3.3 0.4
Table 2 Multivariate analysis of transplantation outcome
(Continued)
Outcome HR 95% CI p
FT 0.6 0.2–1.3 0.2
Donor CMV pos. 1.7 0.99–2.7 0.05
ATG used 0.4 0.2–0.7 0.005
Hazard ratios of the three different conditioning regimens (FLAMSA as
reference) and variables with p values below 0.05 are reported
ATG anti-thymocyte globulin, BM bone marrow, CMV cytomegalovirus, FLAMSA
fludarabine, intermediate dose Ara-C, amsacrine, total body irradiation,
cyclophosphamide sequential regimen, KPS Karnofsky performance status, FT
fludarabine-treosulfan, GVHD graft-versus-host disease, LFS leukemia-free
survival, MSD matched sibling donor, NRM non-relapse mortality, OS overall
survival, PBSCs peripheral blood stem cells, RI relapse incidence, TBF thiotepa-
busulfan-fludarabine, UD unrelated donor
Table 3 Causes of death
FT TBF FLAMSA
Total 75 67 410
Hemorrhage 2 (3%) 2 (3%) 4 (1%)
Failure/rejection 1 (2%) 0 (0%) 2 (1%)
Infection 11 (16%) 18 (27%) 73 (19%)
Interstitial pneumonitis 1 (1%) 2 (3%) 6 (2%)
GVHD 7 (10%) 7 (10%) 31 (8%)
Original disease 40 (59%) 27 (40%) 244 (63%)
VOD 0 (0%) 4 (6%) 8 (2%)
Other transplantation related 5 (7%) 7 (10%) 18 (5%)
Missing 7 0 21
FLAMSA fludarabine, intermediate dose Ara-C, amsacrine, total body
irradiation, cyclophosphamide sequential regimen, FT fludarabine-treosulfan,
GVHD graft-versus-host disease, TBF thiotepa-busulfan-fludarabine, VOD
veno-occlusive disease
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of relapse were age at transplant, relapsed vs primary re-
fractory AML, and patient CMV positive serology. Of
note, the use of ATG did not influence relapse risk.
Leukemia-free survival, overall survival, and GRFS in
the global population were 27%, 34%, and 20%, respect-
ively. Leukemia-free survival at 2 years was similar
among the three groups: 29%, 22%, and 27% for FT, TBF,
and FLAMSA, respectively (p = 0.28). Overall survival
did not significantly differ as well, being 37% for FT, 24%
for TBF, and 34% for FLAMSA (p = 0.10). In multivari-
ate analysis, patient CMV positive serology was associ-
ated with inferior LFS. The factors predicting inferior
OS were KPS lower than 80% and patient CMV positive
serology. The composite endpoint GRFS at 2 years was
23%, 13%, and 20% for FT, TBF, and FLAMSA, respect-
ively (p = 0.15) (Fig. 2). In multivariate analysis, KPS
lower than 80% and patient CMV positive serology were
independently associated with inferior GRFS.
Discussion
Limited data is available to guide the choice of the
conditioning regimen for patients with primary refractory
or relapsed AML. We thus analyzed and compared the
outcome of three commonly used conditioning regimens
for active AML namely fludarabine-treosulfan, thiotepa-
busulfan-fludarabine, and FLAMSA sequential regimen.
Our results indicate global survival of 34% at 2 years; the
type of conditioning protocol did not significantly affect
survival, which was mostly determined by patient
characteristics.
A major obstacle in transplanting patients with active
leukemia is the high risk of non-relapse mortality; in
fact, historical trials employing standard busulfan- or
TBI-based regimens report a NRM rate of approximately
30–40% at day 100 after transplant [24–26]. In our study
including patients up to 76 years of age, NRM at day 100
was around 5% following FT and FLAMSA and 13%
after TBF, this difference being not statistically signifi-
cant. Similarly, NRM at 2 years did not differ among the
three regimens. It is important to highlight that the FT
cohort included significantly older patients as compared
to TBF and FLAMSA groups; in fact, 70% of FT patients
were older than 50 years (median age of FT group, 58
years). Different strategies have been followed by re-
searchers aiming to reduce mortality and improve the
outcome of patients undergoing transplant with persist-
ent leukemia. The design of the sequential FLAMSA
regimen by the German group has represented a major
breakthrough in this setting, combining promising
anti-leukemic activity with acceptable NRM (about 22%
at 2 years) [9]. On the other hand, some recent evidence
suggests that redesigning standard myeloablative regi-
mens could be an alternative strategy [1]. In fact, the
Gruppo Italiano Trapianto di Midollo Osseo (GITMO)
selected the TBF protocol as conditioning regimen for
the GANDALF prospective trial, whose results have
been recently presented, reporting a NRM rate of 35% at
2 years [27]. An alternative regimen is represented by
the combination of fludarabine and treosulfan, which
was shown to provide an interesting safety profile and
promising outcome in patients undergoing transplant in
remission [17] or with persistent leukemia [18, 20].
Importantly, the tolerability of the conditioning regi-
men should not compromise powerful antitumor activity
in patients undergoing transplant with active AML. In
the current study, we observed a complete remission
rate at day 100 of about 90% following FT and FLAMSA,
while CR rate was 80% after TBF, this difference being
not statistically significant. Similarly, survival did not sig-
nificantly differ among the three groups. Two-year sur-
vival rates were around 35% following FT and FLAMSA
protocols; the latter was in accordance with the original
report by the Munich group [8]. Conversely, TBF regi-
men was associated with a survival rate of 24% at 2
years, consistently with recent evidence from the
GITMO trial employing the same protocol (OS at 2
years, 18%) [27]. Incidence of acute and chronic GVHD
did not differ between the three regimens. In previous
reports including patients with AML in remission, FT
protocol has been associated with lower rates of GVHD
as compared to busulfan-based regimens; we could not
confirm this finding in our population of patients under-
going transplant with persistent leukemia [18, 28]. In
fact, previous literature indicates a higher incidence of
GVHD in patients transplanted with active disease in
comparison to patients undergoing transplant in remis-
sion [29]. Nevertheless, we observed a tendency towards
better GRFS following the FT protocol.
The rather large cohort included in the present study
has allowed us to perform a multivariate analysis on fac-
tors predicting transplant outcome in the setting of ac-
tive AML. Karnofsky performance score below 80% and
patient positive CMV serology were strongly associated
with poor survival. Further, patients with relapsed AML
showed significantly higher risk of disease recurrence
after transplant as compared to primary refractory AML.
These findings are in accordance with a great body of
previous evidence [30–32]. Transplant from mismatched
UD predicted higher risk of grade III–IV aGVHD and
non-relapse mortality, with no significant impact on sur-
vival. Interestingly, the use of ATG was associated with
significantly lower incidence of both acute and chronic
GVHD and a strong tendency towards better GRFS, with
no influence on relapse rates. The benefit of ATG in
terms of reduced incidence of GVHD is well established
[33, 34]. However, as graft-versus-leukemia correlates
with GVHD, there is a theoretic concern that the use of
ATG could result in increased relapse rates, especially in
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patients undergoing transplant with active leukemia.
Interestingly, in the historical ATG trial by GITMO,
which included a high proportion of patients with active
AML receiving transplant from unrelated donors, the
use of ATG was associated with lower incidence of acute
and chronic GVHD with no impact on relapse [35]. The
findings of the present study are in line with these data.
Furthermore, a recent report on patients with high risk
AML undergoing transplant following a reduced inten-
sity conditioning regimen including ATG confirmed no
increased relapse risk [36]. Finally, it is of interest that in
our cohort of patients aged up to 76 years, age at trans-
plant did not influence survival, indicating that older age
should not be taken as a criterion to withhold transplant
in patients with active AML.
The limitations of the present study are mostly related
to its retrospective design; in fact, limited information is
available on the reason why a specific patient was allo-
cated to a certain regimen. Further, scarce data on
minimal residual disease status after transplant was
available in the database; similarly, information on treat-
ment administered after transplant other than cellular
therapies (i.e., chemotherapy, target therapies, hypometi-
lating drugs) was incomplete. Nevertheless, since a pro-
spective randomized study comparing the three different
conditioning protocols in patients with active AML has
not been conducted yet and it is unlikely to be per-
formed in the near future, we believe the results of the
present analysis might serve to guide physicians practice
in this very high-risk patients.
In conclusion, allogeneic transplant should be strongly
considered in primary refractory and relapsed AML, as
it is able to provide long-term survival in about one
third of these patients. FT, TBF, and FLAMSA represent
three possible alternative conditioning options in this
setting, providing similar efficacy, toxicity, and survival.
In fact, outcome was strongly affected by patient charac-
teristics including Karnofsky performance score and
Fig. 1 Transplant outcome following FT, TBF, and FLAMSA regimens. RI relapse incidence, NRM non-relapse mortality, LFS leukemia-free survival,
OS overall survival. RI: p=0.33; NRM: p=0.24; LFS: p=0.28; OS: p=0.10
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CMV serology, while age should not be taken per se as a
criterion to select patients for transplant. The use of
ATG was associated with reduced incidence of severe
acute and chronic GVHD without influencing relapse
risk. Relapse remains the major cause of transplant fail-
ure; novel post-transplant strategies are thus in need to
prevent disease recurrence in this extremely high-risk
population.
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